185 related articles for article (PubMed ID: 37813900)
21. LncRNA TUG1 interacting with miR-144 contributes to proliferation, migration and tumorigenesis through activating the JAK2/STAT3 pathway in hepatocellular carcinoma.
Lv J; Kong Y; Gao Z; Liu Y; Zhu P; Yu Z
Int J Biochem Cell Biol; 2018 Aug; 101():19-28. PubMed ID: 29791864
[TBL] [Abstract][Full Text] [Related]
22. The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells.
Liu Z; Ning F; Cai Y; Sheng H; Zheng R; Yin X; Lu Z; Su L; Chen X; Zeng C; Wang H; Liu L
Cancer Commun (Lond); 2021 Jan; 41(1):62-78. PubMed ID: 34236149
[TBL] [Abstract][Full Text] [Related]
23. BCLAF1 binds SPOP to stabilize PD-L1 and promotes the development and immune escape of hepatocellular carcinoma.
Yu Z; Wu X; Zhu J; Yan H; Li Y; Zhang H; Zhong Y; Lin M; Ye G; Li X; Jin J; Li K; Wang J; Zhuang H; Lin T; He J; Lu C; Xu Z; Zhang X; Li H; Jin X
Cell Mol Life Sci; 2024 Feb; 81(1):82. PubMed ID: 38340178
[TBL] [Abstract][Full Text] [Related]
24. LncTUG1 contributes to the progression of hepatocellular carcinoma via the miR-144-3p/RRAGD axis and mTOR/S6K pathway.
Chen W; Bai Z; Bai W; Wang W; Guo J; Guo M; Sai Y; Shi J; Wu J
Sci Rep; 2023 May; 13(1):7500. PubMed ID: 37160972
[TBL] [Abstract][Full Text] [Related]
25. Dickkopf-1 drives tumor immune evasion by inducing PD-L1 expression in hepatocellular carcinoma.
Yang RH; Qin J; Cao JL; Zhang MZ; Li YY; Wang MQ; Fang D; Xie SQ
Biochem Pharmacol; 2023 Feb; 208():115378. PubMed ID: 36513141
[TBL] [Abstract][Full Text] [Related]
26. The hypoxia-inducible factor 1 inhibitor LW6 mediates the HIF-1α/PD-L1 axis and suppresses tumor growth of hepatocellular carcinoma in vitro and in vivo.
Xu H; Chen Y; Li Z; Zhang H; Liu J; Han J
Eur J Pharmacol; 2022 Sep; 930():175154. PubMed ID: 35868447
[TBL] [Abstract][Full Text] [Related]
27. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
Liu H; Shen J; Lu K
Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
[TBL] [Abstract][Full Text] [Related]
28.
He L; Xu K; Niu L; Lin L
Pharm Biol; 2022 Dec; 60(1):1710-1720. PubMed ID: 36086826
[TBL] [Abstract][Full Text] [Related]
29. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
30. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.
Umemoto Y; Okano S; Matsumoto Y; Nakagawara H; Matono R; Yoshiya S; Yamashita Y; Yoshizumi T; Ikegami T; Soejima Y; Harada M; Aishima S; Oda Y; Shirabe K; Maehara Y
J Gastroenterol; 2015 Jan; 50(1):65-75. PubMed ID: 24509608
[TBL] [Abstract][Full Text] [Related]
31. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
[TBL] [Abstract][Full Text] [Related]
32. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
33. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
[TBL] [Abstract][Full Text] [Related]
34. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
Liu J; Liu Y; Meng L; Liu K; Ji B
Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705
[TBL] [Abstract][Full Text] [Related]
35. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
36. Bioinformatics Analysis Identifies
Guo S; Yang Q
Front Biosci (Landmark Ed); 2024 Jan; 29(1):39. PubMed ID: 38287833
[TBL] [Abstract][Full Text] [Related]
37. microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3.
Li Y; Zhou T; Cheng X; Li D; Zhao M; Zheng WV
Bioengineered; 2022 Mar; 13(3):4730-4743. PubMed ID: 35184646
[TBL] [Abstract][Full Text] [Related]
38. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
Li Q; Han J; Yang Y; Chen Y
Front Immunol; 2022; 13():1070961. PubMed ID: 36601120
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8
Cheng CC; Ho AS; Peng CL; Chang J; Sie ZL; Wang CL; Chen YL; Chen CY
Int Immunopharmacol; 2022 Nov; 112():109110. PubMed ID: 36037651
[TBL] [Abstract][Full Text] [Related]
40. FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1.
Guo C; Zhou N; Lu Y; Mu M; Li Z; Zhang X; Tu L; Du J; Li X; Huang D; Xu Q; Zheng X
Biomed Pharmacother; 2024 Jan; 170():115955. PubMed ID: 38048735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
